Navigation Links
Cytopia Nominates JAK2 Clinical Candidate for Myeloproliferative Disorders
Date:3/17/2008

sed into formal preclinical studies including IND-enabling toxicology studies. This program will lead to the submission of an Investigational New Drug (IND) application with the US Food and Drug Administration(FDA) in the fourth quarter of 2008. The preclinical development program has already been considered by the FDA in pre-IND reviews, including a face-to-face meeting with FDA reviewers last month.

"The accumulated data for CYT387 clearly indicates that this compound has an excellent potency and safety profile for the treatment of patients with MPDs. We are aggressively progressing this compound through formal preclinical studies with the aim of beginning clinical trials by the end of this year," said Mr. Andrew Macdonald, CEO of Cytopia.

About JAK2

The discovery of a specific single activating mutation in the JAK2 enzyme in MPDs in 2005 has focused attention on developing a therapy for these diseases through selective inhibition of JAK2. To successfully address these chronic diseases with a JAK2 inhibitor, the specificity and resultant tolerability profile is a key element of the product profile required for a "best in class" inhibitor.

CYT387 is a specific JAK2 inhibitor with excellent potential for safe and efficacious chronic human dosing. It has been derived from Cytopia's knowledge of basic biology of JAK kinases, a strong structural biology program that has delivered multiple co-crystal structures of JAK2 complexed with inhibitors, and the subsequent development of an extensive chemical library of JAK2 inhibitors through an integrated computational and medicinal chemistry platform.

Cytopia is developing a suite of JAK2 inhibitors for multiple indications including the treatment of certain cancers, particularly lymphomas and solid tumors where JAK2 has been shown to be up-regulated, and for cardiovascular diseases such as pulmonary hypertension.

About Cytopia

Cytopia Ltd is an Australian biotechnology company
'/>"/>

SOURCE Cytopia Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmacopeia Nominates Novel Chemokine Receptor Antagonist for Development
2. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
3. Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously
4. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
5. Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic Cancer
6. Northern California Foot and Ankle Center Santa Rosa Enrolling Patients With Chronic Diabetic Foot Ulcers for Matrix Clinical Research Trial
7. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
8. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
9. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
10. New Clinical Studies Presented at the 14th World Congress of Anesthesiology Demonstrate Masimo Advancements in Patient Care
11. Ception Therapeutics Initiates Phase II/III Clinical Trial for Its Lead Product Reslizumab in Eosinophilic Esophagitis (EE) in Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... , 21. November 2014 /PRNewswire/ ... hat heute bekannt gegeben, dass die ... EMA) die Kennzeichnung als Orphan-Medizinprodukt an ... des Unternehmens zur Behandlung von Fibrodysplasia ... seltene, stark beeinträchtigende genetische Krankheit, die ...
(Date:11/21/2014)... MELVILLE, N.Y. , Nov. 21, 2014 /PRNewswire/ ... of the world,s largest health care services companies, and ... world,s largest provider of health care products and services ... announced that the companies have entered into a long-term ... service and product offerings to office-based medical practices.  This ...
(Date:11/21/2014)... research firm Kalorama information says that 2014 will be ... medical device industry.  The firm thinks the $360 billion-dollar ... growth this year, which led firms to look to ... entrance by acquisition into new competitive zones.  The company ... Global Market for Medical Devices, 5 th Edition ...
Breaking Medicine Technology:Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 2Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 3Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 4Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 5Kalorama: 2014 The "Year of The Buy" in Medical Device Industry 2
... The Intellectual Property portfolio of TIGR® Matrix ... the granting of a second U.S. patent related to ... was developed based on the hypothesis that soft tissue ... mechanical load – a process known as ,mechanotransduction, which ...
... PRGO;TASE) today announced that it has received final approval ... abbreviated new drug application (ANDA) for Desloratadine tablets (5 ... upon its filing of an ANDA containing a Paragraph ... the terms of the settlement, Perrigo can commercially launch ...
Cached Medicine Technology:Novus Scientific Announces a New U.S. Patent for a Mesh Implant Comprising Two Different Resorbable Materials with Different Degradation Times and Specific Mechanical Behaviours; U.S. Patent No. -- 8,083,755 2Perrigo Announces FDA Final Approval for Desloratadine 2
(Date:11/21/2014)... DC (PRWEB) November 21, 2014 Midway ... Atlantic Information Services, Inc.’s (AIS) annual Directory of Health ... plan market. AIS’s Directory of Health Plans is a ... health plans operating in the U.S. The 2015 ... far, researchers in AIS’s Directory and Databases Division, the ...
(Date:11/21/2014)... Recently, DressVe.com , a renowned women’s dress wholesaler ... collection of fashion accessories. Furthermore, the company has launched its ... off, on all its fashion items. Also, orders above $59 ... of the company, their wedding dresses and prom dresses are ... greatly discounted rates. , The CEO says “We are ...
(Date:11/21/2014)... November 21, 2014 TopConsumerReviews.com recently ... an industry leader in the relief of ... significant feelings of sadness and depression each year ... pharmaceutical choices. Often, prescription drugs can produce worse ... drugs are expensive and require regular follow-up visits ...
(Date:11/21/2014)... 21, 2014 First Choice Emergency ... today. The new facility is located at 225 E. ... , “We are pleased to join the Friendswood community ... medical care here,” said Dr. Siddiqi, Facility Medical Director ... To celebrate the opening, First Choice Emergency Room made ...
(Date:11/21/2014)... HealthDay Reporter THURSDAY, Nov. 20, 2014 (HealthDay ... much more likely to have a child who suffers from ... it looks like environment may play a greater role than ... are overweight teach behaviors, and those behaviors are passed on," ... fellow at the Framingham Heart Study, Boston University and the ...
Breaking Medicine News(10 mins):Health News:Data from Atlantic Information Services’s Forthcoming Directory Shows Volatility in U.S. Health Care Market 2Health News:DressVe.com Announces Its 2014 Special Friday Sales 2Health News:Depression Relief Product Receives Top 5-Star Rating from TopConsumerReviews.com 2Health News:First Choice Emergency Room Opens New Facility in Friendswood, Texas 2Health News:Kids Born to Overweight Moms May Face Higher Heart Risks as Adults 2
... those with trouble organizing thoughts, but not memory loss ... pressure may predict dementia in older adults with impaired ... not in those with memory problems, a new study ... average age 83, who were followed-up for five years. ...
... regimen is followed, , MONDAY, Feb. 8 (HealthDay News) -- ... whole grains, fish and fruit -- may protect aging brains ... , Other studies have already found that such diets also ... , The latest study was led by Dr. Nikolaos ...
... , OWINGS MILLS, Md. , Feb. 8 ... portion-controlled weight-loss program, today announced the launch of Medifast Brownies ... list of dessert options available on the Medifast 5 & ... Meals. The Brownies are available for purchase at http://www.choosemedifast.com/ ...
... , Feb. 8  A measure to make roads ... or ability or whether traveling by car, bus, bike or on ... The "Complete Streets" bills, SF 2461 and HF 2801, are supported ... advocates who attended an afternoon press conference. , "We live on ...
... , , SANTA ANA, Calif. ... (NYSE: IM ) is pleased to announce a new ... wholly-owned subsidiary of Quality Systems, Inc. ( QSII). NextGen Healthcare is ... management systems, connectivity solutions and revenue cycle management services for hospitals, ...
... , Feb. 8 The Whittemore Peterson Institute ... Moore , a distinguished women,s health expert, as its new ... its efforts to help raise awareness and funding for its ... Syndrome.   , "We are pleased to have a highly ...
Cached Medicine News:Health News:High Blood Pressure May Predict Dementia in Some Seniors 2Health News:Mediterranean Diet May Help Keep You Smarter 2Health News:Medifast Adds Freshly Prepared Brownie to Meal Replacement Line 2Health News:Medifast Adds Freshly Prepared Brownie to Meal Replacement Line 3Health News:Broad Coalition Praises Complete Streets Bill Introduced in Minnesota Legislature 2Health News:Broad Coalition Praises Complete Streets Bill Introduced in Minnesota Legislature 3Health News:Broad Coalition Praises Complete Streets Bill Introduced in Minnesota Legislature 4Health News:Broad Coalition Praises Complete Streets Bill Introduced in Minnesota Legislature 5Health News:Ingram Micro and NextGen Healthcare Team Up to Influence the Swift Adoption of Electronic Healthcare Records in U.S. 2Health News:Ingram Micro and NextGen Healthcare Team Up to Influence the Swift Adoption of Electronic Healthcare Records in U.S. 3Health News:Ingram Micro and NextGen Healthcare Team Up to Influence the Swift Adoption of Electronic Healthcare Records in U.S. 4Health News:Ingram Micro and NextGen Healthcare Team Up to Influence the Swift Adoption of Electronic Healthcare Records in U.S. 5Health News:Whittemore Peterson Institute Announces Renowned Health Expert as New Spokesperson 2
The Medtronic CardioRhythm Marinr Catheter is intended for use in diagnostic electrophysiologic procedures. These catheters are designed for recording intracardiac electrograms and temporary pacing a...
... catheter is specifically designed for use with ... EP deflectable NAVI-STAR catheter houses a Biosense ... indicate, in real time, exact location points ... local electrogram information. The NAVI-STAR electro-anatomical navigation ...
For Atrial Mapping. Biosense Webster offers a complete line of specialty 20-pole catheters. The CRISTA CATH 20-pole deflectable catheter is designed for positioning along the crista terminals....
... Steerable Catheter. Steerable atrial mapping ... designs and a unique 45 ... to 24 electrodes, regular and ... active tip electrodes, and bipolar ...
Medicine Products: